For US residents only.

How Treatment May Help

KYMRIAH

How well does KYMRIAH work?

Because other treatment options have not kept your cancer in remission, the goal of KYMRIAH® (tisagenlecleucel) therapy is long-term remission of your cancer. Studies first began in 2012, and Novartis has since treated many patients with CAR-T therapy. Since 2015, KYMRIAH has been studied in a global clinical trial of children and young adults with relapsed or refractory B-cell ALL, with many achieving an early and lasting remission. Click each button below to see the results of the KYMRIAH clinical trial. While many patients have been successfully treated with KYMRIAH, not all patients will respond the same way.

52 of 63 children and young adults ‭treated with KYMRIAH had their cancer go into remission. For nearly ‭everyone, remission happened between ‭26 and 31 days after KYMRIAH infusion.

All 52 of those in ‭remission after KYMRIAH ‭had undetectable levels ‭of cancer left in their ‭bone marrow (MRD–).*‬‬‬‬

*Doctors can use highly sensitive tests to look for traces of cancer in bone marrow called minimal ‭residual disease or MRD. These tests give a very precise measure of remission that may indicate to ‭your treatment team how well KYMRIAH is working.‬

46 of the 52 children and ‭young adults who went into ‭remission after treatment with ‭KYMRIAH did not need an ‭allogeneic transplant.‬‬‬‬‬

  • 6 months after remission, children and young adults have more than a 75% estimated chance of still being in remission as estimated during the trial follow-up. Trials are still ongoing to see how long remissions last
  • 6 months after infusion, children and young adults have an 89% estimated chance of still being alive as estimated during the trial follow-up. Trials are still ongoing to see if patients live longer with treatment
How has KYMRIAH helped kids like me?

KYMRIAH has helped kids with the same type of cancer that you have. Not everyone's experience is the same but, for many kids, it helped them beat their cancer.

 

Share your KYMRIAH story

Sometimes, hearing other families’ experiences with relapsed or refractory B-cell ALL can make all the difference to a new patient. If you would like to share your family’s story, please call 1-844-606-3339 or e-mail Inspire@hastrategies.com.